It is very uncertain whether S‐1 changes tumour response compared with 5‐FU‐containing regimens (very low certainty).
S‐1 showed no clear difference in progression‐free survival compared with 5‐FU‐containing regimens (low certainty).
S‐1 showed no clear difference in time‐to treatment failure compared with 5‐FU‐containing regimens (low certainty).
Combination showed no clear difference in treatment‐related death compared with single‐agent chemotherapy (moderate certainty).
S‐1 showed no clear difference in treatment‐related deaths compared with 5‐FU‐containing regimens (moderate certainty).
S‐1 showed no clear difference in treatment discontinuation due to toxicity compared with 5‐FU‐containing regimens (high certainty).
5‐FU/cisplatin/anthracycline combinations probably leads to lower overall survival compared with 5‐FU/cisplatin combinations (without anthracyclines) (moderate certainty).
5‐FU/cisplatin/anthracycline combinations may leads to higher tumour response compared with 5‐FU/cisplatin combinations (without anthracyclines) (low certainty).
5‐FU/cisplatin/anthracycline combinations may leads to lower time to progression compared with 5‐FU/cisplatin combinations (without anthracyclines) (low certainty).
Metronidazole probably leads to lower symptomatic cure with all exclusions treated as failures compared with vancomycin (moderate certainty).
It is very uncertain whether metronidazole changes bacteriologic cure compared with vancomycin (very low certainty).
It is very uncertain whether metronidazole changes cure (combined symptomatic and bacteriologic cure) ‐ mild disease compared with vancomycin (very low certainty).
It is very uncertain whether metronidazole changes cure (combined symptomatic and bacteriologic cure) ‐ severe disease compared with vancomycin (very low certainty).
It is very uncertain whether teicoplanin changes symptomatic Cure compared with vancomycin (very low certainty).
It is very uncertain whether teicoplanin changes bacteriologic Cure compared with vancomycin (very low certainty).
Fidaxomicin probably leads to higher symptomatic Cure compared with vancomycin (moderate certainty).
It is very uncertain whether bacitracin changes symptomatic Cure compared with vancomycin (very low certainty).
Probiotics probably leads to lower incidence CDAD: complete case compared with control (moderate certainty).
Probiotics showed no clear difference in CDAD (baseline risk 0‐2%) compared with control (moderate certainty).